2019-nCoV Envelope protein (N-His&Avi) (STJP000024)
SPECIFICATIONS
HostE.coli
ConjugationUnconjugated
ImmunogenRecombinant SARS-CoV-2 (2019-nCoV) Envelope Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Val75) of SARS-COV-2 (2019-nCoV) Envelope (Accession #QHD43418.1) fused with an initial Met, a 6ΓHis, Av
General Information
| Short Description | 2019-nCoV Envelope-N-His&Avi protein was developed in e.coli using the region Met1-Val75. For use in research applications. |
| Host | E.coli |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Conjugation | Unconjugated |
| Formulation | Supplied as a 0.22 Mu m filtered solution in 20mM Tris, 250mM NaCl, 0.5%TritonX-100, pH 8.0. |
| Storage Instruction | Store at-20Β°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Immunoreactivity | Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 Envelope at 2 Mu g/mL (100 Mu L/well) can bind Recombinant SARS-CoV-2 Nucleocapsid with a linear range of 1.2-41.1 ng/mL. |
| Determination Method | < 0.1 EU/Mu g of the protein by LAL method. |
Target Information
| Immunogen | Recombinant SARS-CoV-2 (2019-nCoV) Envelope Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Val75) of SARS-COV-2 (2019-nCoV) Envelope (Accession #QHD43418.1) fused with an initial Met, a 6ΓHis, Av |
| Immunogen Region | Met1-Val75 |
| Immunogen Sequence | MYSFVSEETGTLIVNSVLLF LAFVVFLLVTLAILTALRLC AYCCNIVNVSLVKPSFYVYS RVKNLNSSRVPDLLV |
Additional Info
| Background | Recombinant SARS-CoV-2 (2019-nCoV) Envelope Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Val75) of SARS-COV-2 (2019-nCoV) Envelope (Accession #QHD43418.1) fused with an initial Met, a 6ΓHis, Avi tag at the N-terminus. |
Information sourced from Uniprot.org